DAX+0,09 % EUR/USD0,00 % Gold-0,98 % Öl (Brent)+0,60 %

Novartis to acquire Xiidra, expanding front-of-eye portfolio and strengthening leadership in eye care

Nachrichtenquelle: GlobeNewswire
09.05.2019, 00:20  |  704   |   |   

Novartis International AG / Novartis to acquire Xiidra, expanding front-of-eye portfolio and strengthening leadership in eye care . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement.

  • Xiidra (lifitegrast ophthalmic solution) 5% fits strategically within industry-leading USD 4.6 billion Novartis ophthalmic pharmaceutical portfolio, laying groundwork for front-of-the-eye pipeline products currently in development[1]
     
  • Xiidra is the first and only prescription treatment approved for both signs and symptoms of dry eye disease with a mechanism of action that targets inflammation[2]
     
  • Xiidra achieved USD 0.4 billion of revenue in 2018 and is well positioned for blockbuster potential; closing expected in second half of 2019, subject to satisfaction of customary closing conditions, including regulatory approvals
     
  • Deal terms include a USD 3.4 billion upfront payment with potential milestone payments of up to USD 1.9 billion
  • Basel, May 9, 2019 - Novartis announced today that it has entered into an agreement with Takeda Pharmaceutical Company Limited to acquire the assets associated with Xiidra (lifitegrast ophthalmic solution) 5% worldwide. Xiidra is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease[2]. The transaction would bolster the Novartis front-of-the-eye portfolio and ophthalmic leadership. Closing of the transaction is expected in second half of 2019, subject to customary closing conditions including regulatory approvals. On closing, Novartis plans a smooth transition of operations and integration of Xiidra into its pharmaceuticals portfolio.

    Dry eye is a common inflammatory disease that, left untreated, can become extremely painful and lead to permanent damage to the cornea and vision[3]. This damage manifests in the form of signs that can be objectively measured by eye care professionals through various clinical tests (such as corneal staining), and symptoms (such as pain and discomfort). Xiidra, with its anti-inflammatory mechanism of action, is the first dry eye treatment approved to treat both the signs of eye damage and the physical symptoms experienced by patients. Additional benefits of Xiidra, exhibited in phase III studies, include a timely onset of action and well-tolerated safety profile.

    Seite 1 von 5
    Wertpapier
    Novartis
    Mehr zum Thema
    USDTwitter


    0 Kommentare

    Schreibe Deinen Kommentar

    Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

     

    Disclaimer

    Meistgelesene Nachrichten des Autors

    Titel
    Titel
    Titel
    Titel